Myomin, an aromatase reducer supplement, for women's health.
This eventually led to the advent of bioidentical hormones, a safer and more natural way to replace hormones. Yet despite this more natural method, the risks are not completely eliminated. However, we can reduce the risks associated with HRT use, both synthetic and bioidentical.
Myomin is an herbal supplement demonstrated to reduce aromatase expression and estrogen levels as well as improve estrogen-dominant conditions like cysts, fibroids, and endometriosis. It can be safely taken with HRT to minimize its associated risks. Many health-care practitioners recommend Myomin with the safe use of hormones. At four different conventions in 2010, Jonathan Wright, MD, the pioneer of bioidentical hormone replacement therapy (BHRT), has discussed the use of Myomin with BHRT to correct hyperaromatization.
Hyperaromatization is excessive conversion of testosterone and DHEA into estrogens. For individuals on hormone therapy, this can be problematic for a number of reasons. First, they are not retaining the hormones that they need. Second, they are accumulating more estrogen than necessary, which can lead to increased risk for conditions like cysts, fibroids, and endometriosis. According to Wright, hyperaromatization is also almost always accompanied by insulin resistance, another added risk. (1)
This is why Myomin is useful for HRT users in order to reduce hyper-aromatization. Myomin functions as an aromatase reducer and estrogen blocker. As seen in Figure 1, some hormones, such as androstenedione and testosterone, are aromatized into forms of estrogen. If this aromatization continues unopposed, excessive estrone (E1) and estradiol (E2) production occurs, increasing the risk for conditions like cysts, fibroids, and even tumors.
[FIGURE 1 OMITTED]
By reducing aromatase expression, Myomin can inhibit these conversions. E1 and E2 levels are kept at optimal levels while estriol (E3), the good estrogen, continues to be produced unopposed. Although considered a weak estrogen, E3 has been found to also reduce menopausal symptoms. Furthermore, it acts as an anticarcinogen in the presence of estradiol. Suzanne Somers, in her book Knockout: Interviews with Doctors Who are Curing Cancer and How to Prevent Getting It in the First Place, shared how she has been able to protect herself against cancer by keeping adequate levels of E1, E2, and most especially E3.
As an estrogen blocker, Myomin competes with estrogen molecules at the receptor sites, minimizing the effect of estrogen on certain tissues. Abnormal growths that are fueled by estrogen, for example, will be effectively stopped.
There is plenty of evidence supporting Myomin's efficacy in reducing aromatase expression, in lowering E2 levels, and on cysts, fibrocystic breasts, uterine fibroids, and endometriosis.
Myomin Reduces Aromatase Expression
An in vivo study demonstrates that Myomin inhibits the aromatase enzyme in the ectopic endometrium and ovarian tissue of rats. Image analysis shows elevated aromatase expression in the positive control group (108.9 and 149.8, respectively) in both tissues (Table 1). After administration of Myomin for 28 days, aromatase expression reduced to 34.7 in the endometrium and 47.0 in the ovary. This translates to a 100% reduction of aromatase expression in the endometrium and an 85.6% reduction in the ovary compared to the negative control. (2)
Table 1: Aromatase Expression in Ovarian and Ectopic Endometrium Tissues Measured through Grayscale Values Tissue Negative Positive Myomin Overall Control Control Group aromatase Group Group reduction by Myomin Ectopic 48.0 108.9 34.7 100% endometrium Ovary 29.7 149.8 47.0 85.6%
Myomin Reduces Estradiol: Animal and Clinical Studies
In one animal study, 90 female mice were given Myomin for 30, 60, and 180 days. Their average E2 level after each period was 50,6, 36.6, and 32.4 pg/ml, respectively. Their E2 level progressively reduced and then stabilized. Each group was then given Myomin for 30, 60, and 180 days, respectively.
A human study involved 60 postmenopausal women with cysts and fibroids. After only 10 days on Myomin, their average E2 level reduced by 47.88%. The fibroids, cysts, and the associated pain gradually reduced as well.
Myomin's effect on E2 level is well illustrated in a case study by Dr. J. lannetta, who has a postmenopausal female patient who initially had very high E2 level at 413 pg/mL. After she took Myomin for 14 months, her E2 level reduced to 43 pg/mL
Myomin On Fibrocystic Breasts
Another study involved 45 women with fibrocystic breasts (Figure 2). Their ages ranged from 18 to 52; 65% were under 35. After 6 months, Myomin was effective in 30 cases (60% effective), while improvement was seen in 13 cases (29%). Only five cases did not notice any change in their condition. It is important to note that in this study, Myomin was effective on pre- and postmenopausal women.
Figure 2: Myomin on Fibrocystic Breasts (6 months) 45 Women Effective 60% Improved 30% No Effect 10% Note: Table made from bar graph.
The following case reports illustrate Myomin'5 efficacy on abnormal growths in the breast.
J. Blair, ND, from New Jersey, has a 48-year-old female patient who has always had fibrocystic breasts since she started her period over 30 years ago. A mammogram was not adequate to test her breasts for lumps; she always needed an ultrasound for that. After taking Myomin for 114 years, she reports that this is the first time in her life that a mammogram shows a clear picture, no more denseness at all. Her breast pain was also eliminated and her period has become regular.
A 56-year-old female from Florida had a lump in the left breast, so she started taking Myomin and Angiostop. Angiostop is a sea-cucumber extract shown to effectively inhibit angiogenesis. (3) Seen through thermographic breast imaging (Figure 3), angiogenesis around the area has evidently reduced and the lump has cleared after 4 months.
L. Mann, OMD, from California, has a 42-year-old female patient with a very invasive ductal carcinoma in situ in the left breast, an E2 level of 690, and high levels of progesterone and testosterone. After standard cancer treatments, she took Myomin and Angiostop. After several months, her E2 reduced to 35 and she's now cancer negative.
[FIGURE 3 OMITTED]
Myomin on Ovarian Cysts and Endometriosis
Myomin was given for 3 months to 85 female patients with ovarian cysts. Out of the 85 patients, 40 cases were related to endometriosis (hyatidiform cyst), 44 cases were simple ovarian cysts, and one was ovarian cancer. The cysts and symptoms of 15 patients completely cleared with no recurrence three months after the study. In 34 patients, the size of the cyst reduced by 50% and some of the associated symptoms were relieved.
A 1994 clinical study tested the effect of Myomin on 255 women with ovarian cysts and endometriosis (Figure 4). Myomin was completely effective in 57.6% of the patients after 5 months of use. Some improvement was observed in 34.1 % of the patients. No effect was observed in only 21 patients.
Figure 4. Myomin on Ovarian Cysts and Endometriosis (5 months) 255 Women Effective 57.6 Improved 34.1 No Effect 8.2 Note: Table made from bar graph.
In 2006, Wright had a 62-year-old female RN patient from California who had a 2 cm ovarian cyst. Before she saw Wright, she had undergone conventional treatment for two years with no apparent effect. After Wright gave her Myomin and iodide for 2 to 3 months, the ovarian cyst quickly cleared. She relates that if she had known about the Myomin before, she would not have had to wait for lengthy conventional therapy.
Myomin for Uterine Fibroids
A 2000 study at the Shanghai Medical School was performed on 60 patients with uterine fibroids (Figure 5). It revealed that when Myomin is used in combination with Angiostop, it is 69.2% effective on uterine fibroids that exceed 2.5 [cm.sup.3] in size. Improvement was observed in 19% of the patients.
Figure 5. Myomin and Angiostop on Uterine Fibroids (6 months) 50 Women Effective 69.2 Improved 19 No Effect 11.8 Note: Table made from bar graph.
V. Jefferson, DC, from New York, has a 58-year-old female patient on bioidentical estrogen and progesterone. She had a myoma approximately the size of a 7-month fetus and heavy bleeding. She had already had a 6-pint blood transfusion but was frustrated because she was still bleeding. She was thrilled when only a day after she took Angiostop and Myomin, her bleeding stopped. Since then, her symptoms improved. A year later, her bleeding has stopped and her myoma has significantly reduced in size.
Myomin Increases 2/16 Hydroxyestrogen Ratio
Among premenopausal women, keeping the right balance between 2-hydroxyestrogen and 16-hydroxyestrogen is important to reduce cancer risk. A higher ratio, meaning more 2-hydroxyestrogen than 16-hydroxyestrogen, translates to a lower cancer risk. According to a report from E. Schlabach, DC, from Ohio, patient urine lab tests show that Myomin can increase the 2/16 ratio more quickly and effectively than DIM. With DIM, the patients' 2/16 ratio ranged from 0.6 to 1.0. After two weeks of Myomin use, their ratio increased to over 2.0 to 6.0.
P. Tunbridge, MD, from Australia, has a similar report. He shares one case where he monitored a female patient whose condition has improved using Myomin instead of DIM.
While the 2/16 ratio is used by many doctors, its association with cancer risk is not as well established as aromatase inhibition or reduction. Even so, Myomin still has an effect on the 2/16 ratio, as the above case reports illustrate.
The development of Myomin underwent an unconventional path. It was first developed based on each individual ingredient's traditional use in Chinese medicine. When it was first marketed, its clinical effects on fibrocystic breasts, uterine fibroids, and ovarian cysts were immediately demonstrated. It was not until a few years later that further studies confirmed that Myomin reduces E2 level, allowing it to be effective for the above conditions. Then a few more years after that, in vivo studies showed that the mechanism behind Myomin's effects is aromatase reduction. These studies indicate that Myomin is more of an aromatase reducer than an aromatase inhibitor.
Aromatase reduction enables Myomin to be effective in reducing E2 and in improving estrogen-mediated conditions, as illustrated in clinical studies and doctors' case reports. For ovarian cysts and endometriosis, Myomin was 57.6% effective. For fibrocystic breasts, Myomin was 60% effective. For uterine fibroids, Myomin was 69.2% effective in combination with Angiostop.
Moreover, Myomin has been shown to work quickly in reducing estradiol. E2 reduction results can already be seen two weeks after starting Myomin, as reported by I. Galloway, DPh, from Texas. Sometimes reduction is up to 50%. Wright reports that a urine test can already detect a reduction in E2 one month after starting Myomin. In one case, E2 level reduced from 50 pg/ml to 13 pg/ml. (4), (5)
Its aromatase reduction function also allows Myomin to be effective in both pre- and postmenopausal women for improving thyroid, kidney, ovarian, and liver cysts, and even abdominal fat. In one particular case, K. Kaplan, DC, from Florida, reports that an overweight patient in her 50s took Myomin at a dose of 5 capsules, 3 times daily. After 4 months, she lost approximately 10 lbs of abdominal fat.
It has been clearly demonstrated that Myomin has various applications in women's health, particularly in conditions associated with hormone imbalance. When there is deficiency or excess of hormones, the body's state of homeostasis is affected and disease results. Hormonal imbalance is linked to hyperaromatization in many cases. For instance, HRT is recommended to a woman who is deficient in progesterone, DHEA, estradiol. When there is excessive hyperaromatization, progesterone and DHEA are converted into E1 and estradiol. As a result, the woman is not getting enough of the hormones that she needs and accumulating too much estradiol. This can lead to problems like cysts and fibroids, especially if she has a history of these diseases. Myomin can help correct hyperaromatization and help maintain the right balance of hormones.
Myomin's function as an aromatase reducer also contributes to increasing the estrogen quotient (EQ). An EQ over 1 is associated with lower estrogen-related cancer risk.
As mentioned earlier, keeping the right balance among El, E2, and E3 is important in reducing cancer risk, as in Somers's case. Henry Lemon derived the formula EQ-E3/(E1 + E2). Since E3 becomes anticarcinogenic in the presence of E2, then ideally women should have more E3 than E1 and E2 combined. This is the reasoning behind the estrogen quotient. A higher EQ means that more E3 will be available to sit at the receptors instead of E1 and E2, preventing any adverse effect that they may have on the cells.
Individuals on BHRT need to be aware of this quotient, since hormones such as testosterone, progesterone, and DHEA are eventually converted into E1, E2, and/or E3. It is therefore important to block the pathway to E2 and E1 and allow E3 production in order to increase the quotient.
Myomin accomplishes this goal: it blocks the E1 and E2 by the conversion of androstenedione into E1 and testosterone into estradiol. This means that the production of these two forms of estrogen is reduced. In the meantime, E3 continues to be produced freely. Since there is more production of E3 than there is E1 and estradiol, the EQ increases.
Women on BHRT will find adding Myomin to their regimen to be very beneficial. Not only are they keeping the hormones that they do need, they are also lowering their cancer risk. (6)
There are obviously many applications for Myomin in women's health. Due to its dual action as an aromatase reducer and estrogen blocker, it is a highly recommended supplement for both pre-and postmenopausal women.
(1.) Wright J, Alvarado-Paz L, Sowinski T, et al. Bioidentical hormone replacement therapy (BHRT): common issues and solutions. Townsend Lett. Jan 2010:56-58.
(2.) Chi TT. Myomin: natural aromatase inhibitor for estrogen-related conditions. Townsend Lett. Dec 2009;317:70-74.
(3.) Tong Y, Zhang X, Tian F, et al. Philinopside A, a novel marine-derived compound possessing dual anti-angiogemic and antitumor effects, Int J Cancer. 2005;114: 843-853.
(4.) Wright J. Practical applications for men. Hormone Therapy in Clinical Practice Symposium. April 17, 2010; Seattle, WA.
(5.) Wright J. Testosterone and a few other therapies for older men: safer and effective use. American College for Advancement in Medicine Convention. November 3-7, 2010; Las Vegas, NV.
(6.) Chi TT. Myomin for men and women on bioidentical hormone therapy. J Am Naturopath Med Assoc. Feb 2011.
Dr. Tsu-Tsair Chi is the founder of Chi's Enterprise Inc., a leading nutraceutical company. He earned his PhD in Biochemistry from Waksman Institute of Microbiology at Rutgers State University and then became a board certified naturopathic physician. Beginning in 2002, Dr. Chi became a qualified instructor for continuing education (CE) courses for licensed health care professionals. To learn more, please visit www.chi-health.com or call 714-777-1542.
by Tsu-Tsair Chi, NMD, PhD
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 1, 2011|
|Previous Article:||Eclampsia prevention and cure--and the cover-up that's killing tens of thousands each year.|
|Next Article:||A naturopathic doctor's treatment of Lyme disease.|